We have assembled an expert team of talented individuals
united by a common set of values and goals.
« Rare are opportunities to work with talented individuals on a mission to improve an industry which affects everyone. »
& Chief Executive Officer
& Chief Executive Officer
François-Henri holds an MSc in Management from ESSEC Business School. Prior to founding NOVA, he spent four years with investment bank Lehman Brothers in London and Tokyo where he has developed an expertise in financial engineering, deal structuring & execution. François-Henri has participated in securitization deals across a wide range of assets representing total completed financings in excess of $500 million USD in Europe and Asia.
As NOVA’s cofounder and CEO since 2010, François-Henri has honed a variety of skills ranging from corporate structuring to business development and people management.
& Chief Technology Officer
& Chief Technology Officer
Frederic graduated from Ecole Polytechnique in Paris with an Applied Mathematics Master in Probabilities and Finance.
He then worked for 12 years in financial market modelling and quantitative trading across London, Tokyo and Singapore, most recently as Managing Director for Standard Chartered Bank. During that time Frederic has managed teams of traders, quants, computer scientists and IT engineers to build large yet efficient and scalable analytics and trading frameworks.
His focus is on simulated outcome based reasoning and decision making where model hypothesis are always tested through the prism of scenarios and large scale simulations.
Gregoire brings more than two decades of experience in innovation, strategy, and digital entrepreneurship to the team. He began his career as the founder and CEO of Andrexen, an innovative Unified Communications cloud platform, which he successfully developed in more than 10 countries around the globe. Grégoire then joined telecoms service provider Cirpack, following its acquisition of Andrexen in 2015, as Chief Marketing and Product Officer. He most recently held the position of Chief Strategy Officer at Experty.io, a blockchain-based knowledge sharing platform.
As Chief Operating Officer, Gregoire ensures alignment between Novadiscovery’s strategy, operations and growth objectives, as well as leading the Modeling and Simulation (M&S) team as it embarks on its next phase of expansion.
Gregoire has a Master’s degree in Fundamental Physics from Pierre and Marie Curie University.
Ehud is a venture CFO and corporate strategic advisor in the startup space with experience in healthcare, enterprise SaaS, e-commerce, and high tech. In addition to his angel investing and board work, he has served as CFO of surgical suite data analytics player, Caresyntax, healthcare cash-pay marketplace, Sesame Inc. and ecommerce retailer UNTUCKit, and built and ran the finance org as an early member of the executive team at Flatiron Health, a healthcare IT startup in the pharmacology/oncology space acquired by Roche in 2018.
Prior to joining the startup world, Ehud headed the US Technology Equity Research team at Citigroup where he covered the Comm Equipment and Data Networking sector following similar roles at Morgan Stanley and JP Morgan. Over the course of his 17-yr Wall Street career, Ehud was ranked #1 by Institutional Investor (I.I.) magazine 14 times and was inducted into the Institutional Investor Hall of Fame in its inaugural year in 2011.
Prof. Jean-Pierre Boissel
& Chairman of the Scientific Advisory Board
& Chairman of the Scientific Advisory Board
Jean-Pierre is a cardiologist by training. He was, until recently, an Emeritus Professor of Clinical Pharmacology at the University of Claude Bernard University Lyon 1, and has been a Scientific Director at the French Institute for Health and Medical Research (Inserm) and advisor to the General Surgeon.
Marc is a professor of Neurology at the Grenoble Alpes University. He was the founder and director of the INSERM/DGOS Clinical Research Center (CIC/GCRC) at the University hospital.
He served at the regional ARH level and was the national coordinator to improve stroke care organization in France at the Ministry of Health.
He has been a member of various scientific international editorial boards and is also in charge of scientific publications at NOVA.
Jim has spent over 15 years advancing systems biology modeling and advocating its adoption in pharmaceutical research. Prior to joining NOVA he founded and ran a systems biology modeling consulting company, Clermont, Bosley LLC, serving major pharma/biotech. Prior to this, Bosley served as Vice President of Modeling and Simulation at Rosa & Co., as Sr. Director of Software Products for Pharsight, as a Consulting Engineer for Entelos and as a Senior Engineer in DuPont’s BioChemical Science and Engineering group. He has written several articles and book chapters on QSP modeling.
Jim holds a PhD (Chem. E.) from the University of Texas at Austin, an MSc (E.E.) from the University of California-Irvine, and a BSc (Chem. E.) from the University of Wisconsin. He has taught courses, and is an affiliated faculty member, at the University of Delaware. As SVP Modeling and Simulation, Jim will be supporting Novadiscovery’s expert modelers and programmers with both an understanding of the current state of the art technology, but also with innovative modeling ideas.
Emmanuel has more than 20 years of pharmaceutical industry and academic experience.
He is in charge of strengthening nova’s relationships with pharmaceutical companies to understand their specific requirements for incorporating in silico technology into existing clinical development programs with a view to streamlining the development process through smaller, more effective clinical trials. He also works with regulatory authorities to develop protocols to aid pharmaceutical companies in including clinical simulation data into regulatory dossiers for new drug applications.
Board of directors
Philippe is the CEO of Genelpis since its inception in 2019. He is also a venture partner with the Digital Health venture team of LBO France, which he joined in early 2018 after a distinguished career in healthcare venture capital in the US. He started his business career in 1987 in the pharmaceutical industry, with Sandoz Pharmaceutical and joined in 1993 The Boston Consulting Group as a Manager.
He has made numerous marquis name investments in the healthcare sector over the years (such as Sapient Health Network, ePocrates, Spotfire, Truveris, NxStage Medical, Cephalon, Auxillium Pharmaceuticals) as part of his broader investments activities, first at The Sprout group which he joined in 1995, and then with New Leaf Venture Partners.
In his role of Managing Director he led the spin-off of NLV from Sprout in 2005 and then the fundraising effort of 4 funds totaling over $1billion. Philippe earned an MDPhD degree from University Paris V and an MBA from Columbia University. He is currently a board member of several private companies in France and the US.
Tanja is the CEO of Debiopharm Innovation Fund, the strategic investment fund of Debiopharm located in Lausanne, Switzerland. With 150 million under management, the fund invests in digital health companies that improve patient journey and drug development in oncology and infectious disease areas.
Prior to joining Debiopharm, Tanja was the Managing Partner of Innomedica Ltd, a strategy and transaction consulting company where she worked on various projects with more than 80 life science and healthcare companies globally over 20 years. Tanja graduated from the Aalto University in Helsinki (Formerly the Helsinki University of Technology) with a Masters in Applied Microbiology and Biochemistry.
Isabelle Vitali is Global Head Digital Innovation at Sanofi. With her team, she explores new usages & disruptive technologies by developing & assessing selected innovative digital solutions bringing value for patients, healthcare professionals & Sanofi employees. Prior to joining Sanofi 3 years ago, she oversaw digital transformation and “beyond the drug” strategy at Roche through the development of Medical Devices & Open Data programs, especially in Oncology. Previously, Isabelle held various Business positions at Global & Local levels at Roche and Merck Sharp and Dohme as Head of BU, Marketing, Sales and Market Access in Oncology, Hematology, Rare Diseases, Cardiovascular Diseases & CNS.
In her diverse activities, she works closely with HealthCare Professionals, Hospitals, Academics, Patient Associations but also Tech companies a regularly mentors startups.
Based on her deep expertise in the Pharmaceutical Industry and her passion for Health, Business & Innovation, her main goal is to contribute to build value for patients.
She holds an Executive MBA from HEC Paris.
Tero is the CEO and Board Member of BC Platforms, a company specialized in bioinformatics, genome data management and data science located in Finland. BC Platforms has built a technology platform to answer ground-breaking research questions in next-generation sequencing and genome-wide association studies.
Prior to joining BC Platforms, Tero was the CEO of Aava Group from, one of the largest healthcare service providers in North Europe (2010 to 2012).
Prior to that, Tero was the CEO of Mawell Ltd from 2001 to 2011. Tero is also a board member of several companies and nonprofit organizations in the healthcare industry. Tero graduated from the University of Oulu Finland with a Master in Economics.
Before joining Debiopharm as Chief Development Officer, Angela Zubel worked for Novartis/Sandoz in Munich, where she was a Development Unit Head, Biopharmaceuticals. Beforehand she spent several years at Novartis as Clinical Program Leader responsible for various early oncology programs, was involved in novel-novel drug combinations and accelerated approval process, and served as a deputy Site Head Translational Clinical Oncology in Basel. Prior to Novartis, she worked several years at MerckSerono in Darmstadt, Germany, where she was responsible for Cetuximab late clinical development and filing of Cetuximab in colorectal cancer.
Angela obtained her MD from Jagiellonian University Krakow, Poland, and her PhD from the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Before joining the pharmaceutical industry, Angela worked for several years as a physician and investigator at the Gynecology and Oncology Department of the Clinical University Hospital in Krakow, Poland.